Drug class profile · refreshed daily from federal data

Nitrate Vasodilator

8 molecules in this class, $205.9M combined CY2024 Part D spend across 11.9M claims. Class-level guide below for benefits decision-makers: where the money lives, where the savings live.

Last updated 15 Oct 2026

NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annualOrange Book: weeklyShortages: daily

Class summary at a glance.

Every drug in the Nitrate Vasodilator class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 8tracked in Part D
CY24 Part D spend: $205.9Mcombined across class
Total Rx claims: 11.9M4.7M unique beneficiaries
Generic mfrs (active): 31across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

01

Isosorbide Mononitrate

7.2M Part D claims (CY24) · 2.2M beneficiaries · First FDA approval: 1993-06-30

8 generic mfrs 0 plans require PA

Low NADAC$0.069

→

Avg plan cost$0.389

Part D spend $95.1M 6× spread, current vs floor

Class share

46%

of class CY24 spend

View profile →

02

Nitroglycerin

Brand: NITRO-BID · 3.8M Part D claims (CY24) · 2.3M beneficiaries · First FDA approval: 1989-12-29

16 generic mfrs 1 plans require PA

Low NADAC$0.063

→

Avg plan cost$3.50

Part D spend $69.4M 55× spread, current vs floor

Class share

34%

of class CY24 spend

View profile →

03

Isosorbide Dinitrate

Brand: Isosorbide · 814K Part D claims (CY24) · 238K beneficiaries · First FDA approval: 1978-12-01

5 generic mfrs 0 plans require PA

Low NADAC$0.069

→

Avg plan cost$0.331

Part D spend $41.5M 5× spread, current vs floor

Class share

20%

of class CY24 spend

View profile →

04

Hydralazine and Isosorbide Dinitrate

Brand: BiDil · — Part D claims (CY24) · First FDA approval: 2012-12-05

2 generic mfrs 0 plans require PA

Low NADAC$0.714

→

Avg plan cost$2.53

Part D spend — 4× spread, current vs floor

Class share

0%

of class CY24 spend

View profile →

05

Isosorbide Dinitrate and Hydralazine

— Part D claims (CY24) · First FDA approval: 2022-04-12

Brand-only (no generics) 0 plans require PA

Low NADAC$0.714

→

Avg plan cost$0.714

Part D spend — 1× spread, current vs floor

Class share

0%

of class CY24 spend

View profile →

06

Nitroglycerin Lingual

— Part D claims (CY24) · First FDA approval: 2019-10-09

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

0%

of class CY24 spend

View profile →

07

Nitroglycerin Tablet

Brand: NITROSTAT · — Part D claims (CY24) · First FDA approval: 2024-09-17

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

0%

of class CY24 spend

View profile →

08

Nitroglycerin, Dextrose

Brand: NITROGLYCERIN IN DEXTROSE · — Part D claims (CY24) · First FDA approval: 2018-11-26

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

0%

of class CY24 spend

View profile →

Related questions.

Q&A librarySourced · reviewed quarterly

pricingWhat is NADAC?pricingIs NADAC the same as my PBM cost?pricingWhat is spread pricing?pricingWhat is a NADAC pass-through PBM contract?pricingWhat's the difference between AWP, MAC, and NADAC?pricingWhat is a dispensing fee in a PBM contract?

Browse all canonical questions →